Riskpilot← Back to searchSign inGet full accessProxi Biotech ApS
APSActiveCVR 39859211Skjalm Hvides Gade 12, 3. thResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20184 employeeswww.proxibiotech.com
Revenue 2024
DKK 984K
+89% vs 2023
EBITDA margin
54.2%
+552% vs 2023
Equity ratio
68.0%
Financial strength
Net profit 2024
DKK 427K
+522% vs 2023
| Revenue | DKK 984K | +89% |
| EBITDA | DKK 534K | +552% |
| Net profit | DKK 427K | +522% |
| Total assets | DKK 613K | +180% |
| Equity | DKK 417K | +4312% |
| Employees | 4 | — |
Legal name
Proxi Biotech ApS
CVR number
39859211
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
13. september 2018
Share capital
DKK 40.000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et medlem af direktionen eller af den samlede bestyrelse i forening.
Company purpose
Selskabets formål er at udøve forskning og eksperimentel udvikling indenfor bioteknologi
Address
Skjalm Hvides Gade 12, 3. th
Phone
+4522552202
Email
rj@proxibiotech.com
Website
www.proxibiotech.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 176 | 337 | 461 | 411 | 521 | 984 |
| Staff expenses | -0 | -261 | -240 | -454 | -471 | -439 | -450 |
| EBITDA | 0 | -85 | 97 | 6 | -60 | 82 | 534 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 0 | -85 | 97 | 6 | -60 | 82 | 534 |
| Net financials | 0 | -9 | -12 | -4 | -12 | -13 | 1 |
| Profit before tax | 0 | -94 | 85 | 2 | -72 | 69 | 534 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | 108 |
| Net profit | 0 | -94 | 85 | 2 | -72 | 69 | 427 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Total assets | 0 | 6 | 477 | 198 | 92 | 219 | 613 |
| Equity | 0 | -93 | -9 | -6 | -79 | -10 | 417 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| Short-term debt | 0 | 100 | 486 | 204 | 171 | 229 | 63 |
| Total debt | 0 | 100 | 486 | 204 | 171 | 229 | 72 |
EBITDA margin
54.2%
This company
15.8%
Market median
+243% vs market
20182024
Equity ratio
68.0%
This company
38.2%
Market median
+78% vs market
20182024
Return on equity
102.4%
This company
18.4%
Market median
+457% vs market
20182024
Net profit margin
43.4%
This company
8.1%
Market median
+436% vs market
20182024
Asset turnover
1.60×
This company
1.12×
Market median
+43% vs market
20182024
Debt / equity
0.47×
This company
0.62×
Market median
+24% vs market
20182024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-09-13 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KG Chief Executive Officer | Chief Executive Officer | 2018 | — | — |
AA Management | Management | 2020 | — | — |
RJ Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2025 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Dr RJ Holding ApS | Company | 33.3% | 33.3% | 2025 |
Aminzadeh Holding ApS | Company | 33.3% | 33.3% | 2025 |
Century House Holding ApS | Company | 0.0% | 5.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Aminzadeh Holding ApS
Proxi Biotech ApS Board members of Proxi Biotech ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kasper Gubba Ørtenblad | Chief Executive Officer | 0 companies |
| Aria Aminzadeh | Management | 0 companies |
| Rene Jørgensen | Chief Executive Officer | 0 companies |
| Paul Jefferson Hargreaves | Board of Directors | 0 companies |
| Sten Verland | Chairman | 0 companies |
| Per Bo Pedersen Fischer | Board of Directors | 0 companies |